Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Operating Income: 2021-2025

Historic Operating Income for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to -$7.2 million.

  • Immunocore Holdings' Operating Income rose 15.66% to -$7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.1 million, marking a year-over-year increase of 33.72%. This contributed to the annual value of -$70.5 million for FY2024, which is 18.13% down from last year.
  • Immunocore Holdings' Operating Income amounted to -$7.2 million in Q3 2025, which was up 51.79% from -$14.9 million recorded in Q2 2025.
  • Immunocore Holdings' Operating Income's 5-year high stood at $18,000 during Q4 2021, with a 5-year trough of -$26.5 million in Q1 2024.
  • Moreover, its 3-year median value for Operating Income was -$14.7 million (2023), whereas its average is -$14.2 million.
  • Per our database at Business Quant, Immunocore Holdings' Operating Income crashed by 80.25% in 2024 and then surged by 86.35% in 2025.
  • Quarterly analysis of 4 years shows Immunocore Holdings' Operating Income stood at $18,000 in 2021, then reached -$17.1 million in 2023, then declined by 14.07% to -$19.5 million in 2024, then climbed by 15.66% to -$7.2 million in 2025.
  • Its Operating Income was -$7.2 million in Q3 2025, compared to -$14.9 million in Q2 2025 and -$3.6 million in Q1 2025.